Background: δ-storage pool disease (δ-SPD) is a bleeding disorder characterized by a
| INTRODUC TI ON
Platelets play an important role in hemostasis by forming a platelet plug upon vascular injury. When platelets are activated, they secrete the content of their storage organelles, alpha-and dense granules, to promote further platelet activation and coagulation. 1, 2 One of the molecules secreted from dense granules is ADP, which promotes secondary platelet activation via the P2Y12 receptor and is essential for thrombus stability. 3 Defects in platelet-dense granules can be classified into storage pool disease (δ-SPD) and secretion defects. δ-SPD results from either a decreased number or complete absence of dense granules or a decreased granule content, such as the empty sack syndrome. 4 Secretion defects are associated with a defective release mechanism resulting from impaired signal transduction or granule trafficking. 5 Platelet secretion disorders, in particular dense granule disorders, are the most common inherited platelet function disorders and may be more prevalent than von Willebrand disease. 6 Nonetheless, there is no consensus on the best laboratory practice to detect these disorders, and the methodology is poorly standardized. 7, 8 The current approach to evaluate platelet-dense granule secretion includes lumi-aggregometry and the measurement of ADP and ATP in platelet lysate using bioluminescence. 9, 10 Lumi-aggregometry is currently the most often used method, but cannot distinguish between a decreased granule number or a secretion defect. 9 Measuring ADP and ATP content in platelet lysates will diagnose patients with storage pool deficiency, 11 but is insensitive for secretion defects. 12 Interestingly, many diagnostic laboratories do not measure platelet nucleotide content, resulting in potential underdiagnosis of δ-SPD. 13, 14 In addition, none of these tests can be performed in patients with thrombocytopenia. Another method used to diagnose δ-SPD is to count the total number of dense granules per platelet with whole mount transmission electron microscopy (TEM) 15, 16 . However, this technique is challenging and not widely available. Therefore, there is an unmet need for an easy and rapid diagnostic tool to evaluate platelet dense granule secretion.
Flow cytometry has been recommended by the International
Society on Thrombosis and Haemostasis/Scientific and Standardization Committee guidelines as a tool to diagnose patients with a platelet function disorder, and has been shown to have added value to light transmission aggregometry in diagnosing platelet function disorders. 9, 17 Platelet granule markers, such as CD63 and P-selectin, have also been used in the screening of mild platelet function disorders on the flow cytometer, but require platelet stimulation before analysis. Mepacrine, a fluorescent acridine derivative that binds adenosine nucleotides, 18 has been used to measure platelet dense granule content. Several studies showed decreased platelet mepacrine fluorescence in patients with δ-SPD, [19] [20] [21] [22] and implementation of mepacrine fluorescence in a diagnostic algorithm for platelet function disorders has been proposed. 23 However, although current data on mepacrine fluorescence are promising, the performance of mepacrine fluorescence has not yet been compared with routine diagnostic tests for δ-SPD in a real-life clinical setting. 24, 25 In the present study, we validated a flow cytometric mepacrine fluorescence assay for dense granule content in patients with a suspected platelet function disorder.
| ME THODS

| Participants
| Healthy volunteers
Blood from healthy individuals was obtained via the Mini Donor Service, a blood donation facility for research purposes that is approved by the medical ethics committee of the University Medical Center (UMC) Utrecht. All donors provided written informed consent, in accordance with the declaration of Helsinki, and selfreported to be free from antiplatelet drugs or nonsteroidal anti-inflammatory drugs for at least 10 days before blood donation.
| Patients
Two different patient cohorts were used in this study. Cohort 1 consisted of seven patients with a previously diagnosed δ-SPD (ADP content < 1.7 µmol/10 11 platelets) and was used to provide proof of principle for diagnostic mepacrine fluorescence. Cohort 2 included patients from the Thrombocytopathy in the Netherlands 
Essentials
• Flow cytometry is recommended in the diagnosistic approach of platelet function disorders.
• Prospective validation of mepacrine fluorescence for storage pool disease.
• High negative predictive value of mepacrine fluorescence in diagnosis storage pool disease.
• Mepacrine fluorescence is suitable for exclusion of storage pool disease.
(TiN) study and was used to validate the flow cytometric mepacrine uptake. The TiN study is a nationwide cross-sectional study to col- 
| Blood collection and platelet preparation
Peripheral venous blood from patients and controls was collected with venipuncture into 3.2% sodium citrate Vacutainer tubes (BD Biosciences). Flow cytometric assays were performed in whole blood, whereas the other tests required platelet-rich plasma (PRP).
PRP was obtained by centrifugation of whole blood at 160 g without brake for 15 minutes at 20°C. Platelet-poor plasma was obtained by centrifugation of whole blood at 2000 g for 10 minutes and was used to adjust PRP concentration to 250 × 10 9 platelets/L. All experiments were performed within 1 to 6 hours after blood collection. 
| Flow cytometric determination of dense granule content
| Platelet ADP concentration
One milliliter PRP with a platelet count between 100 and 250 × 
| Quantification of dense granules with TEM
Platelet-dense granule numbers were counted using TEM images made with the Jeol1010 microscope (Jeol). Formvar-coated grids were stabilized with carbon (Edwards Auto306) and coated with 100 μg/mL fibrinogen for 20 minutes at room temperature. Coated grids were blocked with 1% bovine serum albumin in HEPES buffered saline. Platelets were allowed to adhere to the grids for 1 minute, after which the grids were rinsed with demi water and air dried.
Images of 10 platelets at 12,000× magnification were taken for every subject. Six independent individuals were instructed to quantify the dense granule number in all images according to the guidelines for dense granule identification. 26 Observers were blinded to the case or control status of the sample.
| Data analysis
Statistical analysis was performed with GraphPad Prism software, (Table 1) .
Platelet ADP content ( Figure 1A ) was decreased in all patients with δ-SPD, whereas the platelet ATP/ADP ratio ( Figure 1B Based on the area under the receiver operating characteristic (ROC) curve, the optimal diagnostic cutoff for mepacrine fluorescence was 71.2% of normal and 51.3% of normal for mepacrine release. Based on these cutoff values, the diagnostic accuracy for both mepacrine fluorescence and mepacrine release was determined (Table 3) . With a sensitivity of 76.5% (95% CI 50.1-93.2) and a spec- 
| D ISCUSS I ON
In the present study, we show that patients with δ-SPD have both decreased mepacrine uptake and decreased mepacrine release after platelet stimulation compared with healthy controls. Because of the high negative predictive value (NPV), but low positive predictive value, mepacrine fluorescence can be used for exclusion of δ-SPD in patients with a suspected platelet function disorder.
Flow cytometry has been recommended by the International
Society on Thrombosis and Haemostasis/Scientific and Standardization Committee guidelines in the diagnostic workup of patients with platelet function disorders. 9 It has been shown that flow cytometry has added value to the current diagnostic workup of patients with suspected platelet function disorders, but its value in diagnosing δ-SPD in particular has not been validated. 19 We are 
TA B L E 2
Characteristics of patients with a suspected platelet function disorder the first to prospectively evaluate the diagnostic accuracy of flow cytometric mepacrine fluorescence in patients with a suspected platelet function disorder. Previous studies already showed that mepacrine uptake is decreased in patients with δ-SPD. 22, 24, 25 One of these studies compared flow cytometric mepacrine assays with routine diagnostic tests in patients with δ-SPD. 22 Similar to these studies, we found that mepacrine fluorescence allows perfect discrimination between patients with confirmed δ-SPD and healthy controls. In contrast to these findings, the performance of mepacrine fluorescence was inferior to platelet ADP measurements in the prospective evaluation of δ-SPD in unselected patients with a bleeding tendency in whom a platelet function disorder was suspected.
We evaluated both mepacrine fluorescence in resting platelets and mepacrine release after platelet stimulation. Of these two parameters, mepacrine fluorescence seems more specific, because it provides a direct measure of platelet dense granule content without the necessity of platelet stimulation. Mepacrine release requires platelet stimulation and therefore cannot discriminate between impaired platelet activation and a secretion defect, because both result in decreased mepacrine release. This is reflected by the superior diagnostic accuracy of mepacrine fluorescence compared with mepacrine release in unselected patients with a bleeding tendency, in whom other platelet function disorders are common.
The strength of this study is that a selected cohort of patients with a suspected platelet function disorder was used for validation of mepacrine fluorescence. All tests were performed simultaneously and researchers were blinded for the diagnosis; therefore, there was no selection bias in this cohort. A potential weakness of our study is that we used platelet ADP content as a reference test.
As a consequence, we could have missed δ-SPD caused by a secretion defect. Moreover, we could have falsely diagnosed δ-SPD in patients with a decreased metabolic adenosine nucleotide concentration, which is characterized by a low ATP/ADP ratio. This is not likely to have influenced the outcome of our study because application of a more stringent definition of δ-SPD that includes an ATP/ADP ratio > 2 resulted in a similar performance of mepacrine fluorescence. Another limitation of this study is that the diagnosis of δ-SPD was not confirmed in a second visit to our diagnostic center. This may have led to an overestimation of the number of patients with SPD in our study.
We report a high NPV for mepacrine fluorescence, which suggests mepacrine fluorescence can be used to exclude δ-SPD. Our validation cohort consisted of undiagnosed patients with a bleeding tendency in whom a platelet function disorder was suspected and therefore reflects the real-life patient population seen at a tertiary referral center. As a result, the prevalence of δ-SPD in our study population was relatively high (11%) compared with the expected prevalence of δ-SPD in the general population. This might have caused an overestimation of the NPV of mepacrine fluorescence. However, we also found a low negative likelihood of mepacrine fluorescence for δ-SPD (negative likelihood ratio 0.1), which is independent of the prevalence and supports the ability of mepacrine fluorescence to exclude δ-SPD.
The current diagnostic approach for δ-SPD does not include a rapid screening test and could benefit from an additional test such as flow cytometry. Unlike the currently available diagnostic tools, flow cytometry is applicable in thrombocytopenic samples and requires only a small sample volume, allowing rapid exclusion of δ-SPD in children. 27, 28 Our data indicate that flow cytometric analysis is very reproducible, even immediately after blood collection.
Taken together, these data indicate that flow cytometric measurement of dense granule parameters is a potential tool for the screening of δ-SPD. The presented method requires a minimal amount of whole blood and can be used to for the exclusion of δ-SPD and for the selection of patients that require further extensive testing. 
CO N FLI C T O F I NTE
